Navigation Links
Mayo Clinic researchers building melanoma vaccine to combat skin cancer
Date:3/19/2012

ROCHESTER, Minn. -- Mayo Clinic researchers have trained mouse immune systems to eradicate skin cancer from within, using a genetic combination of human DNA from melanoma cells and a cousin of the rabies virus. The strategy, called cancer immunotherapy, uses a genetically engineered version of the vesicular stomatitis virus to deliver a broad spectrum of genes derived from melanoma cancer cells directly into tumors. In early studies, 60 percent of tumor-burdened mice were cured in fewer than three months and with minimal side effects. Results of the latest study appear this week in the journal Nature Biotechnology.

"We believe that this new technique will help us to identify a whole new set of genes that encode antigens that are important in stimulating the immune system to reject cancer. In particular, we have seen that several proteins need to be expressed together to generate the most effective rejection of the tumors in mice," says Richard Vile, Ph.D., a Mayo Clinic researcher in the Department of Molecular Medicine and a coauthor of the study, along with Jose Pulido, M.D., a Mayo Clinic ophthalmologist and ocular oncologist.

Dr. Vile's success with melanoma adds to Mayo Clinic's growing portfolio of experimental cancer vaccines, which includes an active clinical trial of vesicular stomatitis vaccines for liver cancers. Future studies could include similar vaccines for more aggressive cancers, such as lung, brain and pancreatic.

"I do believe we can create vaccines that will knock them off one by one," Dr. Vile says. "By vaccinating against multiple proteins at once, we hope that we will be able to treat both the primary tumor and also protect against recurrence."

The immune system functions on a seek-and-destroy platform and has fine-tuned its capacity to identify viral invaders such as vesicular stomatitis virus. Part of the appeal of building cancer vaccines from the whole spectrum of tumor DNA is that tumors can adapt to the repeated attacks of a healthy immune system and display fewer antigens (or signposts) that the immune system can identify.

Cancers can learn to hide from a normal immune system, but appear unable to escape an immune system trained by the vesicular stomatitis virus with the wide range of DNA used in the library approach.

"Nobody knows how many antigens the immune system can really see on tumor cells," says Dr. Vile. "By expressing all of these proteins in highly immunogenic viruses, we increased their visibility to the immune system. The immune system now thinks it is being invaded by the viruses, which are expressing cancer-related antigens that should be eliminated."

Much immunotherapy research has slowed because of researchers' inability to isolate a sufficiently diverse collection of antigens in tumor cells. Tumors in these scenarios are able to mutate and reestablish themselves in spite of the body's immune system.

The study was a Mayo collaboration with professors Alan Melcher and Peter Selby at the Leeds Institute of Molecular Medicine, University of Leeds, U.K. They were also co-authors.


'/>"/>

Contact: Robert Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. The West Clinic Joins Cancer Clinics of Excellence (CCE)
2. Stethoscope App gives iPhone New Clinical Skills
3. Mayo Clinic responsible for $22 billion in economic impact, including $9.6 billion in Minnesota
4. Sunquest Introduces Integrated Clinical Environment Physician Portal Solution in US
5. Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials
6. Clinical trial underway: Miniature ultrasound device could revolutionize pain relief
7. Sunquest Completes System-Wide Implementation at Cleveland Clinic Hospital Laboratories
8. Michael J. Fox Foundation Awards $1.1 Million For Clinical Trial of Transdermal Nicotine as Disease-Modifying Treatment For Parkinsons
9. NOVAVAX Presents Positive Clinical Results at The World Health Organization Conference, Geneva, Switzerland
10. UCLA Health System Presents: How to Successfully Implement a Clinical Portal
11. International Merchant Advisors CEO Mel Roseman to Discuss New Medical Marijuana Clinics Live on CBS Radio Networks Big Biz Show February 22, 2010 at 1:40 pm PST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Slidell, LA (PRWEB) , ... May 24, 2016 , ... ... which will feature a unique and patented refillable hanging wipe dispenser. The campaign kick-off ... 1, 2016 and will end June 25, 2016. The goal is to raise $1,000 ...
(Date:5/24/2016)... Birmingham, Lake Orion, Clarkston Michigan (PRWEB) , ... ... ... of a new Certified Nurse Midwife, Roberta Jordan. , Roberta Jordan is ... her undergraduate degree from Grand Valley State University and then went on to ...
(Date:5/24/2016)... ... May 24, 2016 , ... Educational opportunities, ... housing, with more advantaged communities providing richer opportunities. Recognizing the key role of ... school improvement policies; (b) school choice policies; (c) school desegregation policies; (d) wealth-focused ...
(Date:5/24/2016)... ... May 24, 2016 , ... Regenerative Medicine is being transformed by ongoing research ... technology, protocols and patient results as have been achieved with Okyanos Cell Therapy ... standard of care for patients worldwide. , As the Medical Advisory Chairman at Okyanos, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Backed ... data logger for each job, ensuring the best suited solution to meet regulatory ... data loggers at their lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... FLINT, Mich. , May 23, 2016 Diplomat ... the third annual Fellowship and Internship programs. The hands-on ... 12. The full-time, paid Fellowship ... Flint, Michigan . Fellows and interns are ... downtown Flint at the Riverfront ...
(Date:5/23/2016)... According to market research ... and Demand Forecast to 2022 - Industry Insights ... (Drug Discovery and Development, Proteomics, Clinical Testing, Environment ... and Biotechnology, Academic and Research Institute, Hospitals and ... mass spectrometry market was valued at ...
(Date:5/23/2016)... -- The World Health Organization (WHO) expanded the Intended Use ... aged 13 years, and above. Effective immediately, the PrePex device, ... adolescent males in the 14 priority countries in Southern and ... male circumcision device to receive WHO Prequalification on 31 May ... said: " The expanded use of PrePex for ...
Breaking Medicine Technology: